To further examine whether DNase I treatment influenced the inflammatory and immune signatures of colitis in the control and DSS-induced mice, we measured the daily fecal levels of lipocalin-2, a sensitive biomarker for intestinal inflammation [26], and the expression of proinflammatory cytokines in the colon tissue of animals at the end of DSS treatment. The gene discussed is LCN2; the disease is colitis.